九典制药(300705) - 300705九典制药投资者关系管理信息20251118

Group 1: Product Performance and Market Strategy - The company’s Loxoprofen Sodium Gel Patch was selected in the 11th batch of national drug centralized procurement with prices set at ¥17.88 for 4 patches, ¥26.82 for 6 patches, and ¥35.76 for 8 patches, with a planned selection quantity of 30.122605 million patches [2] - The company anticipates a certain growth in sales for the Loxoprofen Sodium Gel Patch post-price reduction due to the ongoing growth in the chronic pain treatment market, with actual performance feedback expected after next year's procurement execution [2][3] - The company plans to expand its sales channels and enhance brand building in response to the centralized procurement, leveraging its established multi-channel coverage system [4] Group 2: Financial Impact and Adjustments - The centralized procurement is expected to lead to a phase adjustment in profit margins for the Loxoprofen Sodium Gel Patch, impacting short-term revenue and profit performance [3] - The company is facing pressure to meet its annual targets due to market challenges, prompting a focus on promoting new products and enhancing market penetration through education and optimized product positioning [9] Group 3: Innovation and R&D Initiatives - The company is transitioning towards innovative drug development, establishing multiple R&D centers and focusing on various drug forms and collaboration models [5] - The R&D team consists of over 40 experts with experience in drug design and clinical research, focusing on oncology and chronic disease treatments using small molecules, peptides, and other drug forms [5] - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of next year, with Phase II trials to follow [6] Group 4: Corporate Governance and Employee Engagement - The company is implementing a share repurchase plan to support future equity incentive programs, aiming to align the interests of the company, shareholders, and core team members [7]